University of Münster
CRIS@UM
DE | EN

Franziska Rodner

Current affiliations

  • Institute of Molecular Virology

Publications

The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
Schreiber A; Rodner F; Oberberg N; Anhlan D; Bletz S; Mellmann A; Planz O; Ludwig S (2024)
In: Antiviral Research, 225, 105840-105840. doi:10.1016/j.antiviral.2024.105840
Research article (journal) | Peer reviewed | Published